지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 261 - 266 (6page)
이용수
이 논문의 연구 히스토리 (2)
2017
베타 3 효능제 단독치료에 suboptimal 반응을 보인 과민성 방광 환자에서 저용량 항무스카린제 추가치료의 효용성 : Efficacy of low-dose antimuscarinics add-on therapy in overactive bladder patients with suboptimal response to beta 3 agonist monotherapy
신정현
의학과
2017.01
학위논문
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
신정현
,
김아람
,
주명수
Investigative and Clinical Urology
2017.01
학술저널
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Purpose: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in over-active bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg). Materials and Methods: We enrolled OAB patients with 4-week mirabegron (50 mg) treatment if the patients' symptoms improved, but not to a satisfactory extent (patient perception of bladder condition [PPBC] ≥4). Enrolled patients had 8-week low-dose antimuscarinics add-on therapy (propiverine HCl, 10 mg). Patients recorded 3-day voiding diary at screening, enrollment (after 4 weeks of mirabegron monotherapy) and after 8 weeks of add-on therapy. We assessed the change of PRO (PPBC) as a primary end point and the efficacy of add-on therapy (change of frequency, urgency, urinary urgency incontinence [UUI] based on voiding diary) as a secondary end point. Results: Thirty patients (mean age, 62.3±12.8 years; mean symptom duration, 16.0±12.3 months) were finally enrolled in the study. The mean PPBC value was 4.3±0.4 after mirabegron monotherapy, and decreased to 3.2±1.0 after 8-week add-on therapy. The mean urinary frequency decreased from 10.1±3.1 to 8.8±3, the mean number of urgency episodes decreased from 3.6±1.6 to 1.8±1.2 and the number of urgency incontinence episodes decreased from 0.7±1.0 to 0.2±0.5 after add-on therapy. No patients had event of acute urinary retention and three patients complained of mild dry mouth after add-on therapy. Conclusions: Add-on therapy of low-dose antimuscarinics exhibits good efficacy and safety in patients with suboptimal response after 4-week of mirabegron (50 mg) monotherapy.
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
Abrams P / 2002 / The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society / Neurourol Urodyn 21:167~178
Tubaro A / 2004 / Defining overactive bladder: epidemiology and burden of disease / Urology 64(6 Suppl 1):2~6
Martínez Agulló E / 2010 / Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients / Actas Urol Esp 34:242~250
Maman K / 2014 / Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison / Eur Urol 65:755~765
Drake MJ / 2016 / Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE) / Eur Urol 70:136~145
Tubaro A / 2004 / Defining overactive bladder: epidemiology and burden of disease / Urology 64(6 Suppl 1):2~6
Martínez Agulló E / 2010 / Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients / Actas Urol Esp 34:242~250
Maman K / 2014 / Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison / Eur Urol 65:755~765
Drake MJ / 2016 / Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE) / Eur Urol 70:136~145
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
Investigative and Clinical Urology
2020 .01
-
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
International Neurourology Journal
2015 .01
-
과민성방광의 새로운 약물치료: 미라베그론과보툴리눔 독소
대한의사협회지
2016 .01
-
Factors affecting medication discontinuation in patients with overactive bladder symptoms
Obstetrics & Gynecology Science
2015 .01
-
Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment
Investigative and Clinical Urology
2017 .01
-
Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result
International Neurourology Journal
2015 .01
-
Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients
International Neurourology Journal
2017 .01
-
Relationship between Lower Urinary Tract Dysfunction and Dementia
Dementia and Neurocognitive Disorders(대한치매학회지)
2020 .01
-
Drug therapy of overactive bladder - What is coming next?
Investigative and Clinical Urology
2015 .01
-
Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury
Annals of Rehabilitation Medicine
2019 .01
-
Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
International Neurourology Journal
2017 .01
-
Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
International Neurourology Journal
2018 .01
-
Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
Investigative and Clinical Urology
2021 .01
-
요실금과 과민성방광
대한의사협회지
2015 .01
-
요실금의 경구약물요법
대한의사협회지
2016 .01
-
Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
International Neurourology Journal
2016 .12
-
Assessment of Proportion of Hidden Patients Having Symptoms of Overactive Bladder and Why Has It Been Hidden in Female Outpatients Admitted to Hospital
International Neurourology Journal
2016 .01
-
A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
International Neurourology Journal
2023 .06
-
Updates of Overactive Bladder in Pediatrics
International Neurourology Journal
2023 .03
-
Overactive Bladder Successfully Treated with Duloxetine in a Female Adolescent
Clinical Psychopharmacology and Neuroscience
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0